July 24, 2016 1:41 AM ET

Company Overview of Albert Einstein College of Medicine

Company Overview

Albert Einstein College of Medicine is an educational institution.

1300 Morris Park Avenue

Jack and Pearl Resnick Campus

Bronx, NY 10461

United States

Founded in 1984



Key Executives for Albert Einstein College of Medicine

Professor and Chairman of the Department of Cardiothoracic Surgery
Compensation as of Fiscal Year 2016.

Albert Einstein College of Medicine Key Developments

Jiangsu Hengrui Medicine Announce Collaboration with Albert Einstein College of Medicine to Advance Cancer Research and Drug Discovery

Jiangsu Hengrui Medicine Co., Ltd. announced that they have entered into a research agreement with Albert Einstein College of Medicine (Einstein) to advance cancer treatment. The multi-year cancer research agreement brings together the scientific and clinical capabilities of Einstein and Jiangsu Hengrui Medicine to develop innovative cancer therapies. The immediate goal of this research is to discover new targets and develop therapies in oncology space.

Albert Einstein College of Medicine Wins $1,999,645 Federal Contract

Albert Einstein College of Medicine won a $1,999,645 federal contract from the U.S. Health and Human Services Department's National Institutes of Health, Rockville, Maryland, to conduct a definitive randomized clinical trial of carbon ion radiotherapy versus 3D conformal radiation therapy for locally and advanced unresectable pancreatic cancer.

Actinium Announces Collaboration with Albert Einstein College of Medicine on New Actinium Program

Actinium Pharmaceuticals, Inc. announced collaboration with Albert Einstein College of Medicine on New Actinium Program. The company and Albert Einstein College of Medicine of Yeshiva University started development of an antibody construct labeled with actinium-225 using a novel technology that potentially allows for the expansion of use of the Company's proprietary platform and enables further manufacturing improvements of alpha therapy technology based drug candidates. The first antibody to be labeled using the new technology has potential to be broadly used in the field of hematology/oncology. Preclinical studies of the new technology have demonstrated significant improvements in product's manufacturing while maintaining biological integrity and properties of labeled antibodies. In addition to making the manufacturing process more time and cost efficient, the new technology allows for a greater versatility in adjusting the final constructs to various clinical situations. Clinical trials of drug candidates based on alpha emitting isotopes have already demonstrated significant efficacy with minimal side effects in blood borne cancers, in metastases of solid cancers and in residual disease in solid cancers post-surgery.

Similar Private Companies By Industry

Company Name Region
Aryzta Us Holdings I Corp. United States
!SOLUTIONS! Group United States
"Atlantic Tele-Satellite, Inc. United States
"D" Construction, Inc. United States
"Graham & Associates,Inc" United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Albert Einstein College of Medicine, please visit www.aecom.yu.edu. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.